The central mechanism the review dissects is bioaccumulation, the process by which fish take up metals from water, sediment, and food faster than they can excrete them. Fish absorb dissolved metals primarily across the gills, which are in constant, intimate contact with the surrounding water, while additional uptake occurs through the skin and the gut. Because metals bind to proteins and are stored in organs such as the liver, kidney, gill, and muscle, concentrations inside fish can exceed those in the ambient water by orders of magnitude. Scientists quantify this with two key indicators: the bioconcentration factor, which compares metal levels in fish to levels in water alone, and the bioaccumulation factor, which also accounts for dietary uptake. On top of bioaccumulation sits biomagnification, the stepwise increase in metal concentrations as contaminated prey is eaten by larger predators up the food web. Mercury is the textbook case—methylmercury, its organic and most toxic form, magnifies so efficiently that apex piscivorous fish can carry concentrations thousands of times higher than the water they swim in.

The five metals chosen for the review each follow distinct chemical routes into aquatic systems. Arsenic enters water through geogenic sources such as arsenic-rich bedrock and through anthropogenic activities including mining, pesticide use, and industrial discharge. Mercury is released by coal combustion, artisanal gold mining, and industrial processes, and once in aquatic environments, anaerobic bacteria convert inorganic mercury into methylmercury, the form that penetrates food webs most effectively. Cadmium arrives via metal smelting, electroplating, phosphate fertilizers, and electronic waste. Chromium contamination stems largely from leather tanning, electroplating, and pigment manufacturing, with the hexavalent form, chromium VI, being far more toxic than the trivalent form. Lead persists from leaded fuel legacies, batteries, paint, and mining runoff. The review emphasizes that both anthropogenic and geogenic origins must be understood together, because background geological contributions can mask or compound industrial pollution in any given watershed.

Inside fish, the toxicological consequences unfold at every level of biological organization. At the molecular scale, metals generate reactive oxygen species, overwhelming antioxidant defenses and damaging lipids, proteins, and DNA. Metals also interfere with essential ions: cadmium, for example, mimics calcium and disrupts calcium transport, with studies showing reciprocal enhancement of cadmium uptake and toxicity in trout liver mitochondria. Fish respond by inducing metallothioneins, small cysteine-rich proteins that sequester metal ions, but this detoxification capacity has limits. At the tissue level, the review catalogs classic histopathological damage: gill epithelial lifting and fusion that impair respiration and ion regulation, liver necrosis and vacuolization, and kidney tubular degeneration. Gill damage is particularly significant because the gill is the first point of contact and a sensitive pollution biomarker.

Physiological and behavioral effects extend the damage beyond individual cells. Chronic metal exposure alters blood parameters, suppresses immune function, and impairs reproduction—recent zebrafish studies reviewed in the paper show that dietary arsenic exposure reduces reproductive output and disrupts offspring development across generations. Behaviorally, metals can scramble the chemical alarm signals fish rely on to detect predators; cadmium-exposed juvenile rainbow trout, for instance, fail to mount normal anti-predator responses. Olfactory toxicity is a recurring theme, with cadmium, zinc, arsenic, and chromium all shown to impair the neurobehavioral pathways that larval fish depend on for finding food and avoiding danger. Such sublethal effects may not kill fish outright, but they erode population fitness in contaminated ecosystems.

For humans, the exposure route of greatest concern is dietary—fish and seafood are the dominant source of methylmercury and a significant source of cadmium and arsenic for many populations. The review draws on decades of epidemiological research, including the landmark Faroe Islands studies that documented cognitive deficits in seven-year-old children with prenatal methylmercury exposure, and the Seychelles Child Development Study, which has followed cohorts for decades. Mercury’s cardiovascular risks have also been documented, with studies in eastern Finnish men linking fish-derived mercury intake to lipid peroxidation and increased risk of myocardial infarction. Cadmium targets the kidneys, damaging proximal tubules and causing chronic dysfunction, a process modulated by metallothionein status. Lead’s neurodevelopmental consequences, particularly through disruption of neurotransmitter systems in early life, remain a global concern even at low exposure levels. Hexavalent chromium is associated with respiratory disease, dermatitis, and carcinogenicity through DNA damage pathways.

To translate contamination data into actionable risk, the review evaluates the standard toxicological toolkit: the target hazard quotient, which compares estimated daily intake to a reference dose; the hazard index, which sums hazard quotients across multiple metals to capture mixture effects; and the cancer risk metric for carcinogenic metals such as arsenic, cadmium, and chromium VI. Applied to fish-consuming populations worldwide—from the Gulf of Guinea to the Ganga basin, from Nigerian markets to Bangladeshi estuaries—these assessments repeatedly flag children as a higher-risk group than adults, owing to lower body weight and higher relative consumption. Notably, the review identifies a critical methodological pitfall: most studies report total metal concentrations rather than chemical species. For arsenic, this matters enormously, because the predominant arsenic forms in marine fish are organic arsenosugars and arsenobetaine, which are far less toxic than inorganic arsenic. Relying on total arsenic can overstate toxicologically relevant exposure by roughly an order of magnitude, distorting risk estimates and consumer guidance alike.

On the remediation side, the review compares the major cleanup technologies by efficiency and scalability. Conventional physicochemical approaches—chemical precipitation, coagulation-flocculation, ion exchange, and membrane filtration—remain workhorses for industrial wastewater, but they generate sludge, consume energy, and struggle at low metal concentrations. Adsorption using engineered materials has surged forward, with metal-organic frameworks, amino-functionalized magnetic nanoparticles, carbon nanomaterials, and nanocomposite membranes demonstrating high capacities for lead, chromium, and mercury removal. Biological options offer lower-cost alternatives: microalgae and bacteria biosorb and biotransform metals, plants phytoextract contaminants from soils and sediments, and genetically modified microalgae have been proposed for mercury bioremediation through combined biosorption and biotransformation. Zero-valent iron nanoparticles can sequester multiple metals simultaneously, even when the metals are complexed with natural organic matter. Yet the review is candid about a gap: field-scale performance data for many nanotechnological approaches simply do not exist, leaving laboratory promise unverified in real waterways.

The review closes with a research agenda that reads as a warning to regulators and consumers alike. Standardized, comparable BCF and BAF datasets are lacking, making cross-study synthesis difficult; speciation analysis should replace total-metal measurements, particularly for arsenic in seafood; epidemiological dose-response evidence in fish-consuming populations remains thin, especially for mixture exposures; and climate change may alter metal cycling and uptake in ways not yet captured by monitoring programs. For the billions of people who depend on fish for protein and micronutrients, the message is not to abandon seafood—fish also deliver essential omega-3 fatty acids linked to neurocognitive benefits—but to demand better monitoring, species-specific and site-specific advisories, and cleanup technologies proven beyond the laboratory bench. Heavy metals, the authors make clear, will not degrade away on their own; managing them is a permanent obligation of industrial society.

Subject of Research: Bioaccumulation of heavy metals in fish and associated human health risks

Article Title: Heavy metals in fish: bioaccumulation, toxicity, and human health risk

Article References: Chauhan, V., Dondiyal, P., & Kumari, K. (2026). Heavy metals in fish: bioaccumulation, toxicity, and human health risk. Environmental Monitoring and Assessment, 198(10), Article 1110. https://doi.org/10.1007/s10661-026-15958-y

Image Credits: AI Generated

DOI: 10.1007/s10661-026-15958-y

Keywords: heavy metals, fish, bioaccumulation, biomagnification, methylmercury, arsenic, cadmium, chromium, lead, human health risk, bioremediation, aquatic pollution

Chronic myeloid leukemia arises when a reciprocal translocation between chromosomes 9 and 22, the so-called Philadelphia chromosome, fuses the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. The resulting BCR::ABL1 protein is a constitutively active tyrosine kinase that drives uncontrolled proliferation of myeloid cells. Imatinib mesylate, the first-generation tyrosine kinase inhibitor approved in the early 2000s, binds the ATP-binding pocket of this aberrant kinase and switches off its signaling, converting a once uniformly fatal disease into a manageable chronic condition for the vast majority of patients. Treatment success is typically monitored by measuring levels of BCR::ABL1 transcript through reverse transcriptase PCR, with a deep molecular response, known as a major molecular response, serving as a key benchmark of effective therapy.

The Indian case began, as many do, with a diagnosis of Philadelphia-positive chronic myeloid leukemia and initiation of imatinib therapy. But the diagnostic workup immediately revealed something unusual. Fluorescence in situ hybridization, or FISH, a technique that uses fluorescently labeled DNA probes to detect specific genetic rearrangements in cells, produced an atypical signal pattern that did not fit the standard picture of a simple BCR::ABL1 fusion. Conventional karyotyping, in which chromosomes are stained and examined under the microscope, showed additional cytogenetic abnormalities beyond the expected Philadelphia chromosome, raising the possibility of complex rearrangements and clonal evolution, features that in chronic myeloid leukemia are usually harbingers of disease progression and poor response to therapy.

To resolve the puzzle, the team deployed a systematic combination of the three cornerstone tools of leukemia genetics. Conventional cytogenetics mapped the chromosomal architecture of the leukemic clone. FISH with probes targeting the ABL1 and ETV6 loci revealed the presence of two distinct fusion events rather than one. Finally, reverse transcriptase PCR confirmed at the transcript level that the patient’s cells harbored both BCR::ABL1 and ETV6::ABL1 fusions concurrently. The ETV6 gene, located on chromosome 12, encodes a transcription factor that is itself a frequent partner in pediatric leukemias when fused to ABL1, but the coexistence of ETV6::ABL1 alongside BCR::ABL1 within a single case of chronic myeloid leukemia is exceptionally rare, and the authors emphasize that such dual ABL1-rearranged presentations are seldom documented in the literature.

The clinical implications of this double hit are where the case becomes genuinely paradoxical. On one hand, the patient failed to achieve a major molecular response throughout the entire course of imatinib therapy, a pattern consistent with resistance. The presence of two ABL1-fused transcripts provides a plausible mechanistic explanation: the ETV6::ABL1 fusion, like BCR::ABL1, encodes an activated tyrosine kinase, but the two fusion transcripts may respond differently to the drug, and the additional cytogenetic abnormalities suggest a genetically complex clone whose full burden is not eliminated by imatinib’s inhibition of a single kinase species. In this sense, the case illustrates how cytogenetic analysis can serve as the pivotal tool for uncovering the underlying cause of apparent imatinib resistance, a point the authors single out as the key highlight of their study.

On the other hand, and contrary to what the genetic complexity would predict, the patient demonstrated long-term survival on continued imatinib therapy. Complex rearrangements and additional chromosomal abnormalities in chronic myeloid leukemia are classically associated with accelerated progression, blast crisis, and poor outcomes, yet this patient’s disease followed an indolent trajectory despite persistent molecular evidence of active leukemia. The authors describe this combination, resistance at the molecular level coexisting with a benign clinical course, as a paradox, and it is precisely this tension that makes the case scientifically valuable. It suggests that the biological aggressiveness conferred by dual ABL1 fusions and clonal evolution may not map neatly onto the conventional prognostic framework, and that molecular response benchmarks, while indispensable for most patients, may not tell the whole story in genetically unusual leukemias.

Why might a patient with two active kinase fusions remain clinically stable on a drug designed to inhibit one of them? The report does not claim to fully answer this question, but several considerations emerge from the biology of these fusions. The ETV6::ABL1 fusion, though oncogenic, has been associated in some reported cases with variable clinical behavior, and the relative abundance, kinase domain sequence, and downstream signaling intensity of each fusion transcript may differ substantially between patients. Moreover, imatinib does inhibit ABL1 kinase activity regardless of which partner gene drives its expression, meaning both fusion proteins are pharmacologically targeted to some degree. The persistent failure to reach major molecular response may therefore reflect the sheer genetic burden of a complex clone rather than true pharmacological escape, while the indolent course may reflect that the residual disease retained a chronic-phase biology rather than acquiring the additional hits needed for blast transformation.

Beyond its immediate clinical narrative, the case carries a broader message about diagnostics in the era of targeted therapy. Modern molecular monitoring for chronic myeloid leukemia is built almost entirely around quantitative PCR assays designed to detect canonical BCR::ABL1 transcripts. A patient whose leukemia contains a second, noncanonical fusion could, in principle, have that driver overlooked entirely if workup stops at routine molecular testing. It was the atypical FISH signal pattern, an anomaly that would have been easy to dismiss as technical noise, that triggered the deeper cytogenetic investigation and ultimately revealed the dual fusion architecture. The authors argue that systematic documentation of such rare cases is essential for the efficient management of patients and for evolving the field’s understanding of dual oncogenic drivers in myeloid neoplasms, a sentiment that underscores the enduring value of conventional cytogenetics even in an age dominated by next-generation sequencing.

The report also speaks to a persistent theme in current chronic myeloid leukemia research. As the authors note, the field’s primary focus has been the discovery of new tyrosine kinase inhibitors and the elucidation of mechanisms underlying imatinib resistance, from kinase domain mutations to compound abnormalities. Cases like this one broaden that agenda by showing that resistance-like molecular profiles can arise from structural genomic complexity, including concurrent fusions, rather than from point mutations alone. For clinicians, the practical takeaway is that unexplained failure to achieve molecular milestones on imatinib warrants a full cytogenetic re-evaluation, including karyotyping and extended FISH panels, before assuming classic resistance mechanisms or escalating therapy. For researchers, the case adds to the small but growing catalog of leukemias with multiple ABL1 rearrangements, a population whose natural history remains poorly characterized precisely because it is so rare.

Published as an open-access case report and conducted with institutional ethics approval and patient consent, the study is a reminder that individual patients with unusual biology continue to teach medicine its most unexpected lessons. A leukemia that should have been aggressive behaved gently; a therapy that should have failed clinically succeeded in keeping the patient alive for the long term even as molecular benchmarks remained unmet. Untangling that paradox required nothing more exotic than careful, layered application of karyotyping, FISH, and PCR, the classic triad of leukemia genetics, applied with the persistence to chase an atypical signal pattern to its root. As tyrosine kinase inhibitors continue to evolve and molecular monitoring grows ever more sophisticated, this rare dual-fusion case stands as both a caution against over-reliance on single-marker testing and an argument for keeping the older, slower tools of cytogenetics firmly in the diagnostic toolkit.

Subject of Research: Concurrent ETV6::ABL1 and BCR::ABL1 fusion genes in a rare case of chronic myeloid leukemia with imatinib resistance

Article Title: Concurrent ETV6::ABL1 and BCR::ABL1 in a rare case of chronic myeloid leukemia: a paradox of imatinib resistance and indolent clinical course

Article References: Mohanty, P., Shetty, D., Amare, P., Patkar, N., Tembhare, P., Subramanian, P. G., Punatar, S., Gokarn, A., Jindal, N., & Khattry, N. (2026). Concurrent ETV6::ABL1 and BCR::ABL1 in a rare case of chronic myeloid leukemia: a paradox of imatinib resistance and indolent clinical course. Annals of Hematology. https://doi.org/10.1007/s00277-026-07234-3

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07234-3

Keywords: chronic myeloid leukemia, BCR::ABL1, ETV6::ABL1, imatinib resistance, tyrosine kinase inhibitor, cytogenetics, FISH, karyotyping, reverse transcriptase PCR, clonal evolution, myeloid neoplasms, ABL1 rearrangement

The research, led by Shu-jie Pang, Zhe Sun, and Da-peng Xu of the Eastern Hepatobiliary Surgery Hospital at Naval Medical University in Shanghai, together with colleagues, set out to map the microbial communities residing within hepatocellular carcinoma and to ask whether the composition of those communities differs between patients whose disease recurs very early after surgery and those who remain disease-free. The team collected tumor tissue and paired adjacent non-tumor tissue from 131 patients with hepatocellular carcinoma and subjected the samples to 16S ribosomal RNA sequencing, a technique that reads out a genetic barcode shared by all bacteria and thereby allows researchers to identify which microbial taxa are present in a sample without needing to culture the organisms in the laboratory.

The first finding addresses a lingering controversy in the field. Intratumoral bacteria have been reported in liver cancer before, but studies have disagreed about whether the microbial composition of tumors actually differs from that of the surrounding, apparently healthy liver tissue. In this cohort, the authors found that overall microbial diversity—the number of distinct bacterial types and their relative abundances—did not differ significantly between tumor and normal tissue. What did differ was composition: the identity of the bacterial players shifted between tumor and adjacent tissue, and there was marked inter-individual heterogeneity, meaning that no two patients carried quite the same intratumoral microbial signature. Bacterial composition also overlapped substantially among tumor tissue, adjacent liver tissue, and bile, a pattern consistent with the idea that the biliary tract may serve as a conduit through which microbes reach the liver parenchyma.

The pivotal result, however, emerged when the researchers stratified patients by clinical outcome. When the intratumoral microbiota of patients who experienced very early recurrence was compared with that of patients who did not, one genus stood out: Bifidobacterium. This group of anaerobic, Gram-positive bacteria—famous as a beneficial inhabitant of the healthy human gut—was significantly less abundant within the tumors of patients whose cancer came back very early. In other words, a paucity of Bifidobacterium inside the tumor was associated with the most aggressive postoperative behavior of the disease. The association held up in an external validation dataset generously provided by Professor Yilei Mao and his team at Peking Union Medical College Hospital, strengthening the case that the signal is not an artifact of a single institution’s patient population.

To confirm that the sequencing signal reflected real bacteria rather than contamination, the team turned to fluorescence in situ hybridization, or FISH. This technique uses fluorescently labeled DNA probes that bind to complementary sequences in bacterial ribosomal RNA, allowing the organisms to be visualized directly within sections of tumor tissue under the microscope. The FISH experiments confirmed the physical presence of Bifidobacterium within hepatocellular carcinoma tissue, placing the bacterium inside the tumor microenvironment rather than merely detecting stray DNA that might have been introduced during sample handling.

With the association established, the researchers probed what Bifidobacterium might actually be doing inside the tumor. They divided tumor samples into those with high versus low abundance of the genus and performed transcriptomic sequencing, which measures the activity levels of all human genes expressed in the tissue. This revealed differentially expressed genes and pathways between the two groups, along with differences in the immune cell composition of the tumors as inferred from the expression profiles. Among the most notable molecular findings was that enrichment of Bifidobacterium correlated with reduced expression of BIRC5, the gene encoding baculoviral IAP repeat containing 5, a member of the inhibitor of apoptosis protein family. BIRC5, better known in the literature as survivin, is a well-characterized antagonist of programmed cell death and is frequently overexpressed in cancers, where it helps malignant cells evade the apoptotic signals that would otherwise eliminate them.

The functional implications of that transcriptional signature were tested with two complementary tissue-based assays. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, universally abbreviated as TUNEL, detects the fragmented DNA that is a hallmark of cells undergoing apoptosis, the tightly regulated process of programmed cell death. Immunohistochemistry for cleaved caspase-3, the executioner enzyme that becomes activated only when a cell has committed to the apoptotic pathway, provided an independent readout of the same biology. Both assays told a consistent story: tumors rich in Bifidobacterium showed enhanced apoptotic activity, exactly as predicted by the reduced BIRC5 expression. The convergence of the transcriptomic data with the TUNEL and cleaved caspase-3 staining lends biochemical weight to what might otherwise have remained a purely correlational observation.

The mechanistic picture that emerges is intriguing, if still incomplete. Bifidobacterium is perhaps best known to immunologists for its role in cancer immunotherapy: prior work by other groups has shown that the abundance of this genus in the gut microbiome can determine whether mice and patients respond to immune checkpoint blockade, and fecal microbiota transplantation experiments have implicated it directly in that effect. The new study extends the relevance of this bacterium from the intestinal lumen to the interior of the tumor itself, and from the immune-activation axis to the apoptotic machinery of the cancer cell. If intratumoral Bifidobacterium suppresses survivin expression and thereby lowers the apoptotic threshold of tumor cells, its absence could plausibly permit residual malignant cells to survive the surgical insult and seed very early recurrence—although the authors are careful to note that causality has not been demonstrated and that the finding requires validation in multi-center cohorts.

Several caveats frame the interpretation of the work. The study was conducted at a single Chinese center, and liver cancer etiology varies considerably across the world, with hepatitis B virus dominating in East Asia while hepatitis C, alcohol, and nonalcoholic fatty liver disease drive the disease elsewhere; whether the microbiota-recurrence link generalizes across these different disease backgrounds remains to be seen. The 16S sequencing approach identifies bacteria only to the level of genus or species with limited resolution and cannot by itself reveal what the organisms are metabolically doing. And as with all studies of low-biomass tissues, distinguishing a genuine resident microbiota from environmental or procedural contamination is a persistent methodological challenge—one that the authors addressed with FISH confirmation and careful bioinformatics, but which continues to demand rigor across the field.

Nevertheless, the study opens a concrete translational avenue. If reduced intratumoral Bifidobacterium abundance is confirmed as a predictor of very early recurrence in larger, multi-center studies, it could eventually inform risk stratification after curative resection, identifying the patients who need the closest surveillance or adjuvant therapy. More ambitiously, the result feeds into a growing interest in microbiota-directed interventions—from probiotics to fecal microbiota transplantation—as adjuncts to cancer treatment. For now, the message is a sober and carefully documented one: the bacteria that live within liver tumors are not passive bystanders, and one familiar genus may hold a clue to why some hepatocellular carcinomas refuse to stay gone.

Subject of Research: Intratumoral microbiota and Bifidobacterium abundance in very early recurrence of hepatocellular carcinoma

Article Title: Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma

Article References: Pang, S.-J., Sun, Z., Xu, D.-P., Shi, Y., Si-ma, H., Yang, N., & Yang, Y. (2026). Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma. BMC Medicine. https://doi.org/10.1186/s12916-026-05271-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05271-3

Keywords: hepatocellular carcinoma, intratumoral microbiota, Bifidobacterium, very early recurrence, 16S rRNA sequencing, apoptosis, BIRC5, tumor microenvironment, FISH, immunohistochemistry, liver cancer, microbiome

HER2, a growth factor receptor encoded by the ERBB2 gene, is amplified or overexpressed in roughly 15 to 20 percent of breast cancers. That molecular signature once heralded an aggressive disease course, but the arrival of trastuzumab, pertuzumab, and a growing arsenal of HER2-targeted agents transformed the prognosis. Today, giving these drugs before surgery—neoadjuvant therapy—is standard practice for stage I to III HER2-positive disease, because it can shrink tumors, sometimes eliminating them entirely, and allows oncologists to gauge response in real time. Yet a meaningful fraction of patients still reach the operating table with residual invasive carcinoma in the breast or lymph nodes.

For those patients, the landmark KATHERINE trial established trastuzumab emtansine (T-DM1) as the standard of care, improving invasive disease-free survival and overall survival compared with trastuzumab alone. More recently, the DESTINY-Breast05 trial showed that trastuzumab deruxtecan (T-DXd) outperformed T-DM1 in patients with residual HER2-positive early disease. Critically, however, both frameworks assumed that a tumor classified as HER2-positive before treatment remained HER2-positive afterward. The MD Anderson study directly tested that assumption—and found it wanting.

The research team, led by pathologist Payu Raval and senior author Aysegul Sahin, retrospectively examined 161 patients treated with HER2-targeted neoadjuvant therapy between 2016 and 2025. Sixty-five of them had enough residual invasive tumor for reliable biomarker reassessment. Using the same clinically validated immunohistochemistry protocol applied in routine care, two study pathologists independently scored HER2 expression in the surgical specimens under the 2018 ASCO/CAP guidelines, with a third pathologist resolving any discordant readings. Every equivocal case—those scored IHC 2+—underwent reflex fluorescence in situ hybridization to determine whether the ERBB2 gene remained amplified.

The results were striking. Thirty-seven of the 65 tumors, or 57 percent, showed a change in HER2 status, shifting from overexpression or amplification before treatment to IHC 0, IHC 1+, or IHC 2+ without gene amplification afterward. Only 28 cases, 43 percent, retained clear HER2 positivity. The pattern depended on where tumors started: among the 33 tumors that were strongly HER2 IHC 3+ at baseline, just under half lost HER2, whereas among the 32 tumors classified as IHC 2+/FISH-amplified, more than two-thirds—68.8 percent—did so. Several of the converted tumors even fell into the emerging HER2-ultralow category, expressing barely detectable levels of the protein.

Perhaps the most sobering aspect of the study is what the researchers could not find. When the team compared the HER2-retained and HER2-changed groups across a battery of clinicopathologic variables—age, clinical stage, histologic subtype, Nottingham grade, hormone receptor status, residual cancer burden, and type of surgery—the two groups were essentially indistinguishable. Hormone receptor positivity was common in both, present in 82.1 percent of the retained group and 89.2 percent of the changed group, and the distribution of residual cancer burden categories was nearly identical. In other words, there is no easy clinical flag that tells oncologists in advance which tumors will shed their target.

Why does this happen? The leading explanation is intratumoral heterogeneity: a single tumor can harbor mixed populations of cells with differing levels of HER2 expression and ERBB2 amplification. Potent HER2 blockade wipes out the dependent cells, while subclones with little or no HER2 survive and repopulate the residual disease—a classic case of clonal selection under therapeutic pressure. Supporting this model, a phase II trial of T-DM1 plus pertuzumab found zero pathologic complete responses in tumors with HER2 heterogeneity, compared with 55 percent in homogeneous tumors. Other work has shown that HER2 heterogeneity is far more prevalent in tumors with low-level amplification, which may explain why the IHC 2+/FISH-amplified group in the new study was so vulnerable to status change. Resistant subclones, genomic studies suggest, often exist before treatment even begins.

The clinical stakes are considerable. Current national and international guidelines recommend adjuvant HER2-targeted therapy for residual disease regardless of post-treatment HER2 status, largely because trials like KATHERINE enrolled patients based on their original diagnosis and never required repeat testing. Whether T-DM1 or T-DXd actually benefits tumors that have lost HER2 remains unknown. There are reasons for cautious optimism: antibody-drug conjugates deliver cytotoxic payloads via the HER2 antibody, so even low levels of the protein may suffice for activity, and the DESTINY-Breast04 trial demonstrated survival benefits of T-DXd in HER2-low metastatic disease. Real-world data from China reported remarkably low recurrence rates among patients who continued HER2-directed therapy despite conversion. But preclinical studies complicate the picture, indicating that HER2-low cells may resist ADCs while remaining susceptible to HER2 kinase inhibitors—hinting that combination strategies may ultimately be needed.

Prognostic evidence is equally unsettled. Several meta-analyses have linked HER2 loss after neoadjuvant therapy to worse recurrence-free and overall survival, with hazard ratios approaching 2, and one registry analysis of more than 21,000 Japanese patients found that 21.4 percent of initially HER2-positive tumors became HER2-negative after treatment. Yet other cohorts, including a surgical series from 2021, found no oncologic penalty for losing HER2 positivity, and some even reported better outcomes with reduced expression. These contradictions likely reflect differences in definitions, therapy intensity, and sampling, but they underscore that complete loss and partial reduction of HER2 may carry different prognostic meanings. Intriguingly, one study found that shorter intervals between therapy and tissue sampling were associated with greater HER2 loss, raising the possibility that some of the change is a reversible pharmacodynamic effect rather than permanent clonal elimination.

The MD Anderson authors are careful about their limitations: the study was retrospective, single-institution, and modest in size, excluded residual tumors smaller than 5 millimeters, and lacked outcome data and molecular profiling. Still, their conclusion is pointed. HER2 should be viewed not as a fixed binary label but as a dynamic continuum reshaped by treatment, and routine reassessment of residual disease deserves serious consideration. Prospective randomized phase II and III trials, they argue, are now needed to determine whether patients whose tumors lose HER2 actually benefit from continuing HER2-targeted therapy—or whether, in the era of antibody-drug conjugates, the biopsy taken after neoadjuvant treatment should become the new starting point for every adjuvant decision.

Subject of Research: HER2 biomarker status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy

Article Title: HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer

Article References: Raval, P., Ding, Q., Singh, P., Alrohaibani, A., Sun, H., Ai, D., Wanis, K. N., Zhao, M., Chen, H., Valero, V., Chavez-MacGregor, M., & Sahin, A. (2026). HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer. Breast Cancer Research and Treatment, 219(3), Article 25. https://doi.org/10.1007/s10549-026-08088-z

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08088-z

Keywords: HER2-positive breast cancer, neoadjuvant therapy, HER2 status change, biomarker discordance, immunohistochemistry, FISH, trastuzumab, pertuzumab, antibody-drug conjugates, intratumoral heterogeneity, residual disease, adjuvant therapy

Myxoid leiomyosarcoma, often abbreviated mLMS, is a rare morphological variant of leiomyosarcoma, a cancer arising from smooth muscle tissue. What distinguishes the myxoid variant is its abundant gelatinous stroma, a matrix that separates the neoplastic smooth muscle cells and gives the tumor a deceptively bland appearance under the microscope. While the uterus is the most common primary site, extra-uterine occurrences involving the retroperitoneum, the intra-abdominal cavity, and soft tissues are exceedingly rare. Population-based data confirm this extreme rarity and identify elderly females as the demographic most frequently affected, with the uterus representing the predominant primary site among myxosarcoma subtypes. Because so few cases exist, the clinicopathological behavior of extra-uterine disease remains poorly characterized, and management protocols are largely extrapolated from data on uterine leiomyosarcoma.

The prognosis of myxoid leiomyosarcoma is a subject of genuine scientific debate, and the disagreement is striking. Some clinical series report a highly aggressive course, with five-year overall survival as low as 11.1 percent, driven by a strong propensity for local recurrence and distant metastasis. In contrast, a Norwegian population-based study reported five-year survival approaching 73 percent, slightly more favorable than conventional leiomyosarcoma, and another investigation documented recurrence in only five of twelve cases over follow-up periods ranging from three to nine years. Researchers believe this discrepancy likely reflects heterogeneity in the diagnostic criteria applied across studies and, more fundamentally, underlying molecular diversity within the entity. Large-scale molecular profiling of uterine sarcomas has underscored that molecular classification refines both diagnosis and prognosis, suggesting that the apparent clinical variability of myxoid leiomyosarcoma may mask several biologically distinct subtypes awaiting precise definition.

Diagnostically, the tumor presents formidable challenges because its morphological and radiological features overlap with a spectrum of benign and malignant myxoid lesions, including myxoid leiomyoma, aggressive angiomyxoma, and low-grade endometrial stromal sarcoma. The myxoid matrix imparts low-attenuation characteristics on computed tomography and heterogeneous signal on other imaging modalities, frequently mimicking benign cystic structures or other soft tissue tumors, which renders imaging insufficient for definitive characterization. In the newly reported case, a contrast-enhanced abdominal CT scan revealed a large, poorly enhanced, heterogeneous soft tissue mass measuring 11.8 centimeters in the left peritoneal space, together with a separate complex cystic-solid lesion measuring 5.8 centimeters in the left lower abdomen. The presence of two spatially distinct lesions raised the possibility of a primary intra-abdominal neoplasm with a satellite deposit or multifocal disease, and a CT-guided core needle biopsy could only suggest an atypical myxoid neoplasm without definitive classification.

Definitive answers came only after surgical excision, performed for concurrent diagnosis and treatment. Gross examination of the resected specimen revealed a multilobulated mass with a gelatinous cut surface and a small adjacent satellite nodule. Under the microscope, the tumor showed a spindle cell proliferation with mild nuclear atypia and high mitotic activity, with 26 mitoses counted per ten high-power fields, all embedded within abundant myxoid stroma. Immunohistochemistry, the technique of using antibodies to detect specific proteins in tissue sections, played a pivotal role. The tumor cells displayed strong and diffuse positivity for desmin, a marker of muscle lineage, but were negative for SMA, h-Caldesmon, and SMMHC, a pattern consistent with the incomplete smooth muscle differentiation profile characteristic of myxoid leiomyosarcoma. Unlike conventional leiomyosarcoma, the myxoid variant frequently shows reduced or absent reactivity for these markers while retaining desmin in most cases, an inconsistency that can easily mislead observers unfamiliar with the entity.

The immunophenotype grew more complicated still. The tumor co-expressed the estrogen and progesterone receptors along with CD10 and Cyclin D1, a combination that prompted consideration of endometrial stromal sarcoma, another uterine mesenchymal malignancy with which myxoid leiomyosarcoma is frequently confused. However, the retention of desmin positivity, the morphological context, and subsequent molecular results argued against that diagnosis. Crucially, immunohistochemistry also revealed strong and diffuse nuclear overexpression of the PLAG1 protein, a finding that prompted a dedicated molecular workup. Overexpression of the MDM2 protein was identified as well, but fluorescence in situ hybridization, or FISH, confirmed a PLAG1 break-apart signal consistent with PLAG1 gene rearrangement while demonstrating an absence of MDM2 gene amplification. That combination effectively excluded well-differentiated and dedifferentiated liposarcoma, tumors that can morphologically overlap with myxoid lesions and that are defined by MDM2 amplification.

The PLAG1 rearrangement carries substantial diagnostic weight. Previous molecular studies have identified PLAG1 gene rearrangement in approximately 25 percent of uterine myxoid leiomyosarcoma cases, and it represents a highly specific biomarker that distinguishes this entity from ZC3H7B-BCOR high-grade endometrial stromal sarcoma and from myxoid inflammatory myofibroblastic tumor. Importantly, strong and diffuse nuclear PLAG1 immunoexpression, as observed in this patient, reliably identifies tumors harboring the rearrangement and serves as a practical triage tool before confirmatory FISH is performed. Integrating the histomorphological pattern, the immunophenotype, and the molecular findings, the clinical team rendered a definitive diagnosis of myxoid leiomyosarcoma harboring PLAG1 gene rearrangement, an example of how modern pathology increasingly depends on layered molecular evidence rather than morphology alone.

Of particular clinical significance is the patient’s prior laparoscopic myomectomy, performed two years earlier for a 13-centimeter submucosal uterine myoma. Surgical oncology literature emphasizes that myomectomy is strictly indicated for benign leiomyomas, and that inadvertent surgery on an occult leiomyosarcoma carries the risk of intraperitoneal tumor dissemination even in the absence of morcellation, the mechanical fragmentation of tissue during minimally invasive removal. Tumor cells have been detected in peritoneal fluid following myomectomy alone. The multilesional intraperitoneal distribution observed in this patient, with two spatially separate masses and an adjacent satellite nodule, raises strong suspicion that iatrogenic peritoneal seeding secondary to the prior myomectomy may have contributed to the tumor’s distribution. The authors of the report stress that any leiomyosarcoma diagnosis arising after a prior myomectomy warrants complete surgical re-evaluation, including hysterectomy, and close surveillance for intraperitoneal disease, and that the case reinforces the critical need for accurate preoperative differentiation between benign leiomyoma and leiomyosarcoma, particularly in younger patients with large or atypical uterine masses.

Treatment and outcomes in this case offer a measure of reassurance alongside the cautionary elements. The patient recovered smoothly after her tumor excision, experiencing only transient abdominal distention, and was discharged on the tenth postoperative day. At six-month outpatient follow-up she remained completely asymptomatic, with no clinical or radiological evidence of recurrence. Complete surgical excision with negative margins remains the cornerstone of curative-intent management for localized myxoid leiomyosarcoma, since standardized treatment guidelines for the rare entity remain elusive. For advanced disease, systemic therapy is an important consideration given the high rates of metastatic failure following resection. Doxorubicin has long been the standard first-line agent for metastatic leiomyosarcoma, but the LMS-04 Phase III randomized controlled trial demonstrated that combining doxorubicin with trabectedin significantly improved progression-free survival compared with doxorubicin monotherapy in metastatic or unresectable disease, an advance that should inform treatment planning for patients with unresectable or metastatic myxoid leiomyosarcoma.

The broader lessons of this single case extend well beyond one patient’s chart. The combination of an incomplete smooth muscle immunophenotype, strong diffuse nuclear PLAG1 expression, and confirmatory FISH proved instrumental in establishing a definitive molecular diagnosis that morphology and imaging alone could never deliver. The authors argue that comprehensive molecular workup, including PLAG1 immunohistochemistry and FISH, should be considered in all myxoid intra-abdominal tumors, particularly in patients with a prior history of uterine surgery. At the same time, the prognostic significance of PLAG1 rearrangement itself remains unresolved and, according to the report, warrants dedicated prospective investigation. For clinicians, the case is a reminder that the gelatinous, deceptively bland tumors encountered in the abdomen may conceal a malignant smooth muscle origin, and for surgeons and patients contemplating fibroid removal, it underscores the enduring importance of rigorous preoperative risk stratification before any uterine operation is undertaken.

Subject of Research: Intra-abdominal myxoid leiomyosarcoma with PLAG1 gene rearrangement following prior laparoscopic myomectomy

Article Title: Intra‐Abdominal Myxoid Leiomyosarcoma With PLAG1 Gene Rearrangement Following Prior Laparoscopic Myomectomy: A Case Report and Literature Review

Article References: Hsieh, C.-E., Wu, P.-H., Su, C.-W., Ma, Y.-C., & Huang, H.-Y. (2026). Intra‐Abdominal Myxoid Leiomyosarcoma With PLAG1 Gene Rearrangement Following Prior Laparoscopic Myomectomy: A Case Report and Literature Review. Clinical Case Reports, 14(9), Article e73539. https://doi.org/10.1002/ccr3.73539

Image Credits: AI Generated

DOI: 10.1002/ccr3.73539

Keywords: myxoid leiomyosarcoma, PLAG1 gene rearrangement, leiomyosarcoma, myomectomy, fibroid surgery, peritoneal seeding, molecular diagnostics, FISH, immunohistochemistry, endometrial stromal sarcoma, trabectedin, soft tissue sarcoma

The research team, led by Vijayapandi Pandy of MIT World Peace University in Pune and colleagues at Chalapathi Institute of Pharmaceutical Sciences in Guntur, India, adapted a spectrophotometric method originally developed in 2009 for detecting dopamine in pharmaceutical products, serum, urine, and even bananas. Their innovation lies not in inventing new chemistry but in extending an established, inexpensive technique into the far messier world of biological brain tissue. The work was conceived explicitly for resource-constrained settings, where advanced analytical instruments are unavailable and where the cost barrier of conventional neurochemical assays effectively excludes entire research communities from dopaminergic research.

The chemistry underpinning the assay is elegantly straightforward. Dopamine, chemically known as 4-(2-aminoethyl) benzene-1,2-diol, belongs to the catecholamine family and possesses a catechol structure with notable reducing power. When brain tissue homogenate is mixed with ferric chloride, dopamine acts as a reducing agent, converting ferric iron, Fe(III), into ferrous iron, Fe(II). These freshly generated ferrous ions then react with potassium ferricyanide to form a stable, soluble Prussian blue complex, formally written as KFe(III)[Fe(II)(CN)6]. This deep blue compound absorbs light maximally at a wavelength of 735 nanometers, a region of the spectrum where interference from other endogenous organic molecules in complex tissue extracts is minimal. That spectral selectivity is what makes the method viable for biological matrices rather than only clean pharmaceutical solutions.

To establish the analytical foundation, the researchers prepared a primary stock solution of dopamine hydrochloride at 1000 micrograms per milliliter and generated a series of standard solutions spanning concentrations from 0.1 to 10 micrograms per milliliter. When the absorbance of each standard was measured at 735 nanometers, the resulting calibration curve displayed a robust linear relationship, described by the regression equation Y = 0.08807X + 0.02025 with a coefficient of determination of 0.9760. This linearity, which slightly extends the range reported in the original pharmaceutical assay, indicates that Prussian blue formation follows Beer-Lambert’s law across the working range and that the buffered brain homogenate environment provides a stable medium for the color reaction. The 95 percent confidence intervals for the slope and intercept were narrow enough to support quantitative use in preliminary screening applications.

The biological validation drew on three remarkably different species. Chicken heads were obtained from a licensed slaughterhouse and fish heads, from the species Labeo rohita, came from a local market, while a single male Swiss albino mouse served as the mammalian reference tissue. All tissue was kept ice-cold during transport and dissection to prevent proteolytic degradation of neurotransmitters. Whole brains were homogenized in 0.1 M phosphate buffer at pH 7.4 using a standardized ratio of one gram of tissue per twenty milliliters of buffer, then centrifuged at 2000 revolutions per minute for ten minutes at five degrees Celsius. The resulting supernatants were diluted to 10, 25, 50, and 75 percent working concentrations, and each aliquot was reacted with potassium ferricyanide and ferric chloride for thirty-five minutes at room temperature before absorbance was read against a reagent blank on a standard laboratory spectrophotometer.

The results revealed striking interspecies differences in brain dopamine content. Mouse brain tissue contained the highest concentration, corresponding to 479.3 micrograms of free dopamine per gram of tissue, equivalent to 593.2 micrograms per gram when expressed as dopamine hydrochloride. Fish brain followed with 325.9 micrograms of free dopamine per gram, or 403.4 micrograms per gram as the hydrochloride salt. Chicken brain showed the lowest concentration at 77.4 micrograms of free dopamine per gram, or 95.8 micrograms per gram as dopamine hydrochloride. The authors attribute these differences to the varying densities of dopaminergic neurons and distinct metabolic rates inherent to murine, piscine, and avian central nervous systems, and they note that the values fall within ranges reported in previous studies, though direct comparison with region-specific or chromatographic measurements should be interpreted with caution.

Beyond the analytical numbers, the study carries a quiet but significant ethical dimension. Because chicken and fish brains are readily available as post-mortem byproducts from slaughterhouses and markets, they require no institutional animal ethics approval under Indian CCSEA guidelines. The researchers explicitly propose these tissues as practical substitutes for laboratory rodents during the preliminary stages of method development, optimization, and proof-of-concept experiments. By reducing the number of animals used for teaching, method development, and training, the approach aligns with the 3Rs concept, the internationally recognized framework calling for replacement, reduction, and refinement in animal research. The single mouse used in the study was euthanized by cervical dislocation without anesthetic agents, a deliberate choice to avoid confounding effects of anesthetics on monoaminergic neurotransmission, and the procedure was conducted under an approved institutional ethics protocol.

The authors are candid about the limitations of their preliminary proof-of-concept design. Calibration points were established using single measurements rather than replicates, and comprehensive evaluation of matrix effects, including recovery studies and interference from endogenous biomolecules, was beyond the scope of the present investigation. They also acknowledge that centrifugation at higher speeds, around 10,000 revolutions per minute for twenty minutes at four degrees Celsius, would likely remove more cellular debris and insoluble proteins, reducing matrix interference and improving accuracy. Future studies, they state, will include full analytical validation with triplicate calibration measurements in accordance with internationally accepted guidelines such as ICH Q2(R2) and USP General Chapter 1225, establishing precision, accuracy, linearity, repeatability, and overall reliability, alongside direct comparison with established techniques like high-performance liquid chromatography.

Even with those caveats, the significance of the work lies in its accessibility. A UV-visible spectrophotometer is among the most common instruments found in laboratories worldwide, and the reagents required, potassium ferricyanide and ferric chloride, are inexpensive, stable, and easy to prepare. The assay requires no complex sample preparation, delivers rapid results, and can process multiple dilutions of tissue homogenates with consistent outcomes. For neuropharmacology laboratories evaluating dopaminergic activity in animal models of neurological disorders, particularly in low-resource settings where advanced analytical instruments are unavailable, the method offers a critical balance of simplicity and sensitivity. The researchers suggest it is highly suitable for routine laboratory estimations of dopamine and for preliminary neurochemical screening before committing samples to more sophisticated and costly confirmatory analyses.

The broader implications extend to how science is done, not just what it discovers. As dopamine research continues to drive progress on Parkinson’s disease, schizophrenia, substance use disorders, and the neurobiology of motivation and reward, the bottleneck has often been not ideas but infrastructure. By demonstrating that a century-old iron chemistry reaction can quantify a key neurotransmitter across mammalian, avian, and piscine brain tissues with a simple benchtop instrument, this study lowers the entry barrier for a global community of researchers and educators. If subsequent validation confirms its robustness in complex biological matrices, the humble Prussian blue assay may become a standard first step in neurochemical laboratories that could never otherwise afford to look inside the dopaminergic brain.

Subject of Research: A cost-effective UV spectrophotometric method for quantifying dopamine in avian, piscine, and murine brain tissues

Article Title: A cost-effective UV spectrophotometric method for dopamine estimation in avian, piscine, and murine brain tissues

Article References: Pandy, V., Vanjarapu, H. D., Polimera, C. S., Dukkipati, S., & Thakre, K. (2026). A cost-effective UV spectrophotometric method for dopamine estimation in avian, piscine, and murine brain tissues. Discover Chemistry, 3(1), Article 526. https://doi.org/10.1007/s44371-026-00995-w

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00995-w

Keywords: dopamine, UV spectrophotometry, Prussian blue, potassium ferricyanide, neurochemistry, brain tissue, spectrophotometry, neuropharmacology, catecholamines, low-cost analytical methods, 3Rs principle, animal models

An international team of researchers led by Dmitrii I. Ostromyshenskii and Aleksandra O. Travina of the Institute of Cytology of the Russian Academy of Sciences, together with colleagues from The Center for Bio- and Medical Technologies in Moscow, carried out a genome-wide analysis of tandem repeats in nine species of ranid frogs. The species surveyed span a broad evolutionary range within the family, including the European common frog Rana temporaria, the Cascades frog Amerana muscosa, the Siberianewood frog relative Rana kukunoris, the moor frog relative Pelophylax lessonae, the northern leopard frog Lithobates pipiens, the American bullfrog Aquarana catesbeiana, Aquarana septentrionalis, the wood frog Boreorana sylvatica, and the torrent frog Staurois parvus. This choice of species allowed the team to examine repeat repertoires across multiple genera and lineages, giving the analysis genuine comparative power.

The technical foundation of the study was a systematic computational search for tandem repeats, sequences in which a repeating unit, or monomer, is arranged head to tail in long arrays. Using the Tandem Repeats Finder algorithm on genome assemblies of all nine species, the researchers catalogued thousands of repeat families, characterized their monomer lengths, GC content, array lengths, and copy numbers, and grouped them into families based on sequence similarity. The scale of the result was remarkable. Tandem repeat content in these frog genomes proved to be exceptionally high, and, crucially, it correlated positively with overall genome size. In other words, the frogs with the largest genomes also carried the largest loads of satellite DNA, a finding that supports the long-standing hypothesis that non-coding repetitive sequence accumulation, rather than gene duplication alone, is a major driver of genome size expansion in amphibians.

Perhaps the most eye-catching figure in the study concerns the origin of these repeats. When the researchers searched the repeat monomers against databases of known transposable elements, they found that a very large proportion of the tandem repeats shared sequence homology with transposable element families. Depending on the species, repeats with recognizable transposable element ancestry accounted for between 43 and 91 percent of the total tandem repeat length in the genome. These TE-based tandem repeats, the authors note, correlated not only with genome size but also with overall tandem repeat content, suggesting that the flux of transposable element sequence into satellite DNA is a continuous and quantitatively significant process in ranid evolution rather than a rare curiosity.

The transposable element classes implicated include some of the most widespread mobile genetic elements in eukaryotes: LINEs, or long interspersed nuclear elements; SINEs, or short interspersed nuclear elements; LTR retrotransposons, which move via an RNA intermediate; and MITEs, miniature inverted-repeat transposable elements, along with DNA transposons of the Tc1-Mariner superfamily. Sequence alignments revealed fragments of these elements embedded within repeat monomers and arrays, providing a molecular fingerprint of their conversion into tandemly repeated satellite DNA. The mechanistic picture that emerges is one in which insertions of transposable elements, or fragments thereof, occasionally seed new tandem repeat arrays, which can then expand through processes such as replication slippage, unequal crossing over, and rolling circle-like amplification into large satellite families.

Beyond their sheer abundance, the repeat families displayed a hierarchical pattern of conservation across the nine species. At one end of the spectrum, the team identified widely conserved repeat families whose sequences could be detected by similarity searches in many or even all of the sampled frogs, hinting at ancient repeat lineages that predate the diversification of the family. At the other end, many repeat families were lineage-restricted or entirely species-specific, detectable in only one of the nine genomes. This layered organization, from ancient shared repeats to young species-private satellites, mirrors patterns seen in other organisms and underscores the rapid turnover of satellite DNA, which can expand, degrade, and be replaced over relatively short evolutionary timescales.

Computational mapping of the repeats onto genome assemblies suggested that the tandem repeats were broadly distributed across chromosomes rather than confined to a single genomic compartment. To test this at the cytogenetic level, the researchers performed fluorescence in situ hybridization, or FISH, using probes derived from representative repeat families. The FISH experiments confirmed the in silico predictions, showing that both the transposable element-derived repeats and the repeats without detectable TE homology occupy pericentromeric regions near the centromeres, subtelomeric regions near chromosome ends, and interstitial positions along chromosome arms. This widespread chromosomal distribution distinguishes the frog repeats from the classic model of satellite DNA as material concentrated exclusively at centromeres.

The comparative presence-absence analysis across the nine species, compiled in a BLAST score-based matrix in the supplementary materials, allowed the team to quantify how repeat families diverge in sequence similarity between relatives and how quickly new families appear in individual lineages. Species such as Rana temporaria, Amerana muscosa, and Staurois parvus served as reference points for characterizing the transposable element composition of their repeat arrays, and the patterns consistently reinforced the conclusion that TE-derived satellites are a pervasive feature of ranid genomes. The coexistence of conserved and lineage-restricted repeat families, many of which carry transposable element signatures, indicates that transposable elements have been recruited repeatedly, and independently, in the emergence of new satellite repeats throughout the evolutionary history of the family.

The findings carry broader implications for understanding amphibian genome evolution and genome biology in general. Amphibian genomes can reach sizes many times larger than the human genome, and the sustained accumulation and expansion of tandem repeats documented in this study offers a compelling explanation for much of that bulk. More broadly, the study adds frogs to the growing list of organisms in which transposable elements act as raw material for the birth of satellite DNA, contributing to centromere structure, heterochromatin formation, and potentially to the reproductive isolation of lineages through rapid satellite divergence. The work was supported by the Russian Science Foundation under grant 25-24-01071, and all data and supplementary tables, including family-by-family repeat catalogues and comparative matrices, are openly available alongside the open-access publication, providing a valuable resource for anyone seeking to decode the repetitive architecture of these extraordinary genomes.

Subject of Research: Genome-wide analysis of tandem repeat repertoires and transposable element contributions in ranid frog genomes

Article Title: Extensive tandem repeat repertoires in ranid frogs and the role of transposable elements in their evolution

Article References: Ostromyshenskii, D. I., Ivanova, N. G., Popova, M. A., Pasynkova, R. A., Podgornaya, O. I., Litvinchuk, S. N., & Travina, A. O. (2026). Extensive tandem repeat repertoires in ranid frogs and the role of transposable elements in their evolution. BMC Biology. https://doi.org/10.1186/s12915-026-02718-0

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02718-0

Keywords: tandem repeats, satellite DNA, transposable elements, Ranidae, amphibian genomes, genome evolution, Anura, FISH, genome size, LINE, SINE, LTR retrotransposons

The Old Brahmaputra is a distributary of the Brahmaputra system that becomes separated from the main flow near Jamalpur and extends through several districts, including Jamalpur and Mymensingh. Its waters provide habitat for fish that use rivers, floodplains and connected wetlands for feeding, spawning, refuge and movement. Bangladesh contains an extensive network of rivers, canals, lakes, estuaries and floodplain habitats, and the country is home to hundreds of native freshwater fish species. Yet these ecosystems face mounting pressure from overfishing, fishing during breeding seasons, pollution, habitat degradation, altered flow and climate-related changes. Previous surveys of the Old Brahmaputra have reported different numbers of species, reflecting differences in geography, timing, sampling effort and fishing gear. The new assessment focused on the Jamalpur Sadar stretch, where the river remains ecologically and economically important but where seasonal fish diversity and environmental variation had not previously been examined together in a recent, site-specific study.

Researchers sampled three sites—Nandina, Nurundi and Pyarpur—located about nine kilometres apart. Fish were collected monthly from local boats using several commonly employed gears: cast nets, seine nets, gill nets, push nets and traps. In total, 4,340 specimens were recorded. The researchers also consulted 30 local fishers through open-ended surveys and focus-group discussions, using local knowledge to confirm species availability and traditional names. Specimens that could not be identified in the field were preserved in buffered formalin and examined in a laboratory using morphometric and meristic characteristics, such as measurements of body proportions and counts of anatomical structures. Sampling was organized around three locally recognized periods: pre-monsoon from March to May, monsoon from June to August and post-monsoon from September to November. Because fishing gears differ in the sizes and species they capture, the results represent a composite view of the exploitable fish community rather than a complete census of every fish inhabiting the river.

The 44 recorded species belonged to 33 genera, 20 families and seven orders. Cypriniformes, the order that includes many carps and minnows, was dominant with 18 species. Siluriformes contributed 11 species, while Anabantiformes contributed eight; Synbranchiformes and Clupeiformes accounted for three and two species, respectively, and Ovalentaria and Cyprinodontiformes were represented by one species each. The most abundant species in the overall catch was Amblypharyngodon mola, a small indigenous fish, while the least abundant was the critically endangered river catfish Bagarius bagarius. That species made up only 0.03 percent of the catch and was recorded only during the post-monsoon period. The conservation profile of the catch was mixed: 59.09 percent of the species were classified as least concern in Bangladesh, but about 29.55 percent fell into vulnerable, endangered or critically endangered categories. Species of conservation concern included Botia dario, Rita rita, Clupisoma garua, Mastacembelus armatus, Ompok pabda, Bagarius bagarius and Labeo boga.

Seasonal comparisons revealed a pattern shaped by the river’s flood pulse. The post-monsoon period produced the highest documented abundance and species richness, followed by pre-monsoon and then monsoon. At first glance, the result may seem surprising because the monsoon brings more water and expands aquatic habitat. Flooding can indeed create spawning and feeding opportunities by connecting the river with floodplains and transporting nutrients into the system. However, fish become dispersed across a much larger area during high water, making them harder to capture in the main channel. As floodwaters recede, fish and other aquatic organisms can become concentrated in remaining channels and pools, increasing both their apparent abundance and the number of species recorded by fisheries sampling. The Bray-Curtis cluster analysis supported this interpretation by showing that pre-monsoon and post-monsoon fish assemblages were more similar to one another than either was to the monsoon assemblage. The reported similarity between the first two groups was 0.86, compared with 0.76 between the monsoon group and the others.

Three diversity measures reinforced the seasonal signal. The Shannon-Wiener index, which combines species richness with the relative balance of abundances, ranged from 2.91 during the monsoon to 3.41 after the monsoon. Pielou’s evenness index increased from 0.84 in the monsoon to 0.91 in the post-monsoon period, indicating that the community was more evenly distributed among species after the flood season. Margalef’s richness index ranged from 4.32 during the monsoon to 5.67 during the pre-monsoon. These indices must be interpreted alongside the sampling method: lower monsoon values do not necessarily mean that fish vanished from the river. Instead, fish may have occupied newly inundated habitats beyond the sampled channel, while high water and stronger flow reduced the efficiency of nets. The researchers also observed species-specific responses. Amblypharyngodon mola was more abundant during the monsoon, when elevated water levels, flooding and nutrient-rich runoff may have created suitable spawning and feeding conditions. Other species, including Macrognathus aculeatus, Channa orientalis and Nandus nandus, were more associated with the pre-monsoon period, whereas Labeo boga, Labeo bata, Mastacembelus pancalus, Xenentodon cancila and Ailia coila were more prominent after the monsoon.

Water-quality measurements help explain why the fish assemblages separated so clearly by season. Researchers measured temperature, pH, dissolved oxygen, total dissolved solids, alkalinity, electrical conductivity and transparency at each site, collecting water samples in triplicate and taking in-situ readings with a calibrated multiprobe. The pre-monsoon period had the highest average water temperature, 30.37 degrees Celsius, and the lowest dissolved oxygen concentration, 5.32 milligrams per litre. It also had the lowest pH, 7.43, and the lowest total dissolved solids, 171.04 milligrams per litre. The monsoon had the highest average pH, 8.68, and the lowest average alkalinity, 91.32 milligrams per litre. Post-monsoon water had the lowest reported temperature, 28.18 degrees Celsius, the highest alkalinity, 97.22 milligrams per litre, and the highest total dissolved solids, reported as 175 milligrams per litre. Electrical conductivity reached 351.76 milligrams per litre after the monsoon, compared with 347.39 before it. Some reported units for conductivity and temperature-related measurements are reproduced as presented in the study.

Statistical analysis identified dissolved oxygen and pH as central variables in the seasonal water-quality pattern. Principal Component Analysis showed that its first axis explained 84.01 percent of the environmental variance, while the second explained 14.57 percent, with dissolved oxygen and pH making major contributions to the separation of seasons. The study also found a strong positive correlation between dissolved oxygen and total fish abundance, with r = 0.949 and statistical significance reported at p < 0.01 in the abstract. Water temperature showed a strong negative correlation with dissolved oxygen, r = -0.874, consistent with a basic property of aquatic systems: warmer water generally holds less oxygen than cooler water. Canonical Correspondence Analysis, a method that relates species distributions to environmental gradients, found that the first two axes explained 71.78 and 28.22 percent of the constrained variation, respectively. The model was statistically significant, and the first axis linked seasonal fish composition with temperature, alkalinity, total dissolved solids, electrical conductivity and pH. These results do not prove that any single variable caused a particular change, but they show that seasonal environmental gradients coincide with predictable shifts in the fish community.

The findings carry practical implications for conservation and fisheries management in the Old Brahmaputra. Protecting habitats used during spawning, nursery development and seasonal migration would help maintain the connectivity on which riverine fish depend. The researchers point to the potential value of fish sanctuaries, protection of migratory habitats, stronger safeguards for threatened species and restrictions on fishing during sensitive periods. They also call for improved knowledge of fish life histories and consideration of measures such as channel excavation or the release of fish fry, although such interventions would require careful ecological assessment. The study’s evidence is a baseline rather than a final diagnosis: it covers one annual cycle, three locations and fishery-dependent catches, so rare, cryptic or gear-avoiding species may have been missed. Nutrient concentrations, flow velocity and habitat structure were not included, and multivariate correlations cannot establish causation. Longer-term monitoring across more sites and years would show whether the seasonal pattern remains stable as climate, river flow and human pressure change. Even with those limitations, the study demonstrates that oxygen, water chemistry and flood-driven connectivity are inseparable from the river’s biological rhythm—and that conserving fish diversity will require managing the river as a changing ecosystem rather than as a static channel.

Subject of Research: Seasonal relationships between fish diversity and water-quality variables in Bangladesh’s Old Brahmaputra River

Article Title: Seasonal variation in fish diversity and hydrological variables of the Old Brahmaputra River, Bangladesh

Article References: Begum, N., Jaman, A., Harun-Al-Rashid, A., Hasan, M. S., Samanta Chandan, C. S., Kunda, M., & Pandit, D. (2026). Seasonal variation in fish diversity and hydrological variables of the Old Brahmaputra River, Bangladesh. Discover Conservation, 3(1), Article 37. https://doi.org/10.1007/s44353-026-00106-x

Image Credits: AI Generated

DOI: 10.1007/s44353-026-00106-x

Keywords: Old Brahmaputra River, Bangladesh fisheries, fish diversity, seasonal ecology, dissolved oxygen, water quality, river conservation, freshwater fish, monsoon hydrology, Seasonal, variation, fish